Nasus Pharma is trading 11% higher at $3.34 on speculative interest and technical buying, despite a lack of fresh filings or press releases as of July 10, 2026.
- The move follows recent volatility, with no new company-specific catalysts reported since June investor forums and a KOL event.
- Previous updates focused on the development of NS002, the company's lead candidate for the treatment of anaphylaxis.